Sign In to Follow Application
View All Documents & Correspondence
View All Documents & Correspondence
Combination Therapy Involving Antibodies Against Claudin 18.2 And Immune Checkpoint Inhibitors For Treatment Of Cancer
Abstract: The present invention provides a combination therapy comprising an anti-Claudin (CLDN) 18.2 antibody and an immune checkpoint inhibitor for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence
Notices, Deadlines & Correspondence
Patent Information
Application #
Filing Date
02 February 2022
Publication Number
10/2022
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
patent@depenning.com
Parent Application
Applicants
ASTELLAS PHARMA INC.
5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
Inventors
1. YAMADA, Tomohiro
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202247005588.pdf | 2022-02-02 |
| 2 | 202247005588-STATEMENT OF UNDERTAKING (FORM 3) [02-02-2022(online)].pdf | 2022-02-02 |
| 3 | 202247005588-SEQUENCE LISTING(PDF) [02-02-2022(online)].pdf | 2022-02-02 |
| 4 | 202247005588-SEQUENCE LISTING [02-02-2022(online)].txt | 2022-02-02 |
| 5 | 202247005588-PROOF OF RIGHT [02-02-2022(online)].pdf | 2022-02-02 |
| 6 | 202247005588-PRIORITY DOCUMENTS [02-02-2022(online)].pdf | 2022-02-02 |
| 7 | 202247005588-FORM 1 [02-02-2022(online)].pdf | 2022-02-02 |
| 8 | 202247005588-DRAWINGS [02-02-2022(online)].pdf | 2022-02-02 |
| 9 | 202247005588-DECLARATION OF INVENTORSHIP (FORM 5) [02-02-2022(online)].pdf | 2022-02-02 |
| 10 | 202247005588-COMPLETE SPECIFICATION [02-02-2022(online)].pdf | 2022-02-02 |
| 11 | 202247005588-FORM-26 [25-04-2022(online)].pdf | 2022-04-25 |
| 12 | 202247005588-FORM 3 [14-07-2022(online)].pdf | 2022-07-14 |
| 13 | 202247005588-Correspondence_Form1_GPA_20-10-2022.pdf | 2022-10-20 |
| 14 | 202247005588-FORM 3 [23-01-2023(online)].pdf | 2023-01-23 |
| 15 | 202247005588-FORM 3 [26-07-2023(online)].pdf | 2023-07-26 |
| 16 | 202247005588-FORM 18 [26-07-2023(online)].pdf | 2023-07-26 |
| 17 | 202247005588-FORM 3 [11-01-2024(online)].pdf | 2024-01-11 |